LeMaitre Vascular

LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. The company was founded by George D. LeMaitre on November 28, 1983 and is headquartered in Burlington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

LeMaitre Vascular reports solid Q4 performance and eyes growth

LeMaitre Vascular's Q4 2022 performance showed growth in sales and income, with strong guidance for 2023.
Despite challenges with gross margin and product line issues, the company is well-positioned for future growth.
Opportunities lie in M&A, sales force expansion, and improving operational efficiency.
Strategic investments have bolstered the company's ability to meet demand and regulatory requirements.

LeMaitre Vascular reports robust Q1 sales and eyes Asia expansion

LeMaitre Vascular delivered strong sales and operating income in Q1 2023, driven by pricing strategies and market expansion efforts.
While facing challenges like rising expenses and competitor risks, the company aims to maintain profitability and drive growth through strategic initiatives.
Opportunities in Asia Pacific expansion and the Aziyo distribution agreement offer avenues for revenue growth and margin improvement.
Overall, LeMaitre's focus on maintaining margins, exploring new markets, and product innovation positions it for continued success in 2023.

LeMaitre Vascular reports robust Q2 sales growth and eyes international expansion

LeMaitre Vascular's Q2 performance reflects strong sales growth, pricing power, and operational efficiency, positioning the company for future success.
While facing margin challenges, the company's diversified product portfolio, international expansion plans, and solid cash position present growth opportunities.
Strategic focus on addressing challenges, optimizing operations, and capitalizing on growth opportunities will be crucial for sustained success and market leadership.

LeMaitre Vascular excels in Q3, eyes growth opportunities ahead

LeMaitre Vascular's Q3 performance was strong, with growth in sales and margins.
The company faces challenges in international markets and sales and marketing dynamics.
Opportunities lie in pricing strategies, product focus, and upcoming product filings.
Overall, LeMaitre Vascular is well-positioned for growth and strategic acquisitions.

LeMaitre Vascular posts strong Q4 results, eyes global expansion opportunities

LeMaitre Vascular's strong performance in Q4 2023 showcases robust sales growth and margin improvement.
While facing challenges such as ongoing impacts from the pandemic and tax rate assumptions, the company is well-positioned for growth.
Strategic initiatives like sales force expansion, APAC expansion, and M&A activities align with opportunities for market penetration and revenue growth.
Guidance for 2024 indicates a focus on operational efficiency and growth strategies to drive continued success.

LeMaitre Vascular excels in Q1 2024, eyes European expansion

Overall, LeMaitre Vascular's Q1 performance showcases strong financial growth, operational improvements, and strategic positioning for future success. The company's focus on expanding its market presence and product approvals sets a positive outlook for continued growth and profitability.

LeMaitre Vascular (LMAT) reports strong Q3 performance and eyes APAC growth

LeMaitre Vascular (LMAT) demonstrated robust sales growth, operational strength, and strategic focus in Q3 2024, positioning itself for continued success. Challenges include pricing strategies and leadership transition, while opportunities exist in sales expansion, regulatory milestones, and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BURLINGTON, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2023 financial results on Wednesday, November 1, 2023, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook.

LeMaitre Will Announce Third Quarter 2023 Earnings Results November 1, 2023

BURLINGTON, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that David Roberts, President, will present at 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023, at 11:40 AM ET in New York City.

LeMaitre to Present at the 2023 Cantor Global Healthcare Conference

LeMaitre Vascular's sales and profits surged in the second quarter. The company's dividend is supported by earnings.

Looking for Dividend Growth? Buy This Little-Known Healthcare Stock

Cigna

Cigna and LeMaitre each appear to have decent growth prospects. Both companies pay well-covered dividends to shareholders.

2 Healthcare Stocks That Could Help Make You a Fortune

LeMaitre Vascular's stock offers attractive long-term investment prospects, with recent consolidations offering an entry point for investors. The company reported record quarterly sales in Q2 and is expected to continue unlocking long-term value for shareholders. LMAT's investment in sales team expansion and continued asset growth contribute to its economic profitability and positive sentiment.

LeMaitre: Record Quarter, ASPs And Volumes Ratcheting Higher Equals Qualified Growth Outlook

LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q2 2023 Earnings Conference Call August 1, 2023 5:00 PM ET Company Participants Joseph Pellegrino - Chief Financial Officer David Roberts - President Conference Call Participants Brett Fishbin - KeyBanc Capital Markets Inc. Aaron Wukmir - Lake Street Capital Markets Michael Petusky - Barrington Research Associates, Inc. Operator Welcome to the LeMaitre Vascular Q2 2023 Financial Results Conference Call. As a reminder, today's call is being recorded.

LeMaitre Vascular, Inc. (LMAT) Q2 2023 Earnings Call Transcript

LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.29 per share a year ago.

LeMaitre Vascular (LMAT) Q2 Earnings and Revenues Beat Estimates

BURLINGTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q2 2023 results, announced a $0.14/share quarterly dividend and provided guidance.

LeMaitre Q2 2023 Financial Results

BURLINGTON, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it is participating in two upcoming investor conferences in August.

LeMaitre to Present at Upcoming Investor Conferences in August

BURLINGTON, Mass., July 17, 2023 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2023 financial results on Tuesday, August 1, 2023, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook.

LeMaitre Will Announce Second Quarter 2023 Earnings Results August 1, 2023

Abbott Labs

Investors interested in Medical - Products stocks are likely familiar with Abbott (ABT) and LeMaitre Vascular (LMAT). But which of these two stocks offers value investors a better bang for their buck right now?

ABT vs. LMAT: Which Stock Should Value Investors Buy Now?

Quanex Building Products

Stellar Bancorp Inc

The iShares Micro-Cap ETF (NYSEARCA: IWC ) is the crème de la crème for finding the top micro-cap stocks to buy. The ETF tracks the performance of the Russell Microcap Index, a collection of the smallest securities in the small-cap Russell 2000 index.

3 Micro-Cap Stocks to Buy Now for Gigantic Growth Potential

LeMaitre continues to add value for shareholders on multiple fronts. The company's business economics support earnings and dividend growth. Looking ahead, the company could be worth $85 intrinsic value.

LeMaitre: Continues To Create Value, Breakout To New Highs

Advance Auto Parts

Clearway Energy

NextEra Energy

Analyst ratings are a wonderful contrarian indicator.

Why The Best Dividend Stocks Are Hated By Analysts

BURLINGTON, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it is participating in two upcoming investor conferences in June.

LeMaitre to Present at Upcoming Investor Conferences in June

LeMaitre Vascular logged impressive sales growth in the first quarter. The company could maintain outsize payout growth in the future.

Is This Healthcare Stock a Buy for Dividend Growth Investors?

Does LeMaitre Vascular (LMAT) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes LeMaitre Vascular (LMAT) a Strong Momentum Stock: Buy Now?

LeMaitre credited a beefed-up sales force and an uptick in hospital orders for higher numbers. The company grew revenue by 19% year over year in the first quarter.

Why Shares of LeMaitre Vascular Are Up Wednesday

LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q1 2023 Earnings Conference Call May 2, 2023 5:00 PM ET Company Participants Joseph Pellegrino - Chief Financial Officer George LeMaitre - Chairman and Chief Executive Officer David Roberts - President Conference Call Participants Brett Fishbin - KeyBanc Capital Markets Inc. Frederick Wise - Stifel, Nicolaus & Company, Inc. Michael Petusky - Barrington Research Associates, Inc. Scott Henry - ROTH Capital Partners Operator Welcome to the LeMaitre Vascular Q1 2023 Financial Results Conference Call. As a reminder, today's call is being recorded.

LeMaitre Vascular, Inc. (LMAT) Q1 2023 Earnings Call Transcript

LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.27 per share a year ago.

LeMaitre Vascular (LMAT) Q1 Earnings and Revenues Beat Estimates

BURLINGTON, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2023 results, announced a $0.14/share quarterly dividend and provided guidance.

LeMaitre Q1 2023 Financial Results

Zimmer Biomet Hlds

Investors with an interest in Medical - Products stocks have likely encountered both Zimmer Biomet (ZBH) and LeMaitre Vascular (LMAT). But which of these two stocks offers value investors a better bang for their buck right now?

ZBH or LMAT: Which Is the Better Value Stock Right Now?

BURLINGTON, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants and services, announced today it has entered into an agreement with Aziyo Biologics, Inc. (Nasdaq: AZYO) to become the exclusive distributor of Aziyo's cardiovascular patches in the United States. Under the agreement, LeMaitre will distribute the products for three years and has an option to acquire Aziyo's worldwide cardiovascular patch business during the second and third year of the term.

LeMaitre to Distribute Aziyo Biologics' Cardiovascular Patches

BURLINGTON, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its first quarter 2023 financial results on Tuesday, May 2, 2023, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook.

LeMaitre Will Announce First Quarter 2023 Earnings Results May 2, 2023

Amgen

Amgen and LeMaitre Vascular both possess solid product portfolios and pipelines to drive future earnings growth. Their payouts are well-covered by their earnings.

News for LeMaitre Vascular Stock (LMAT)